Clinical Trials Stemming from our Lab Work

GPRC5D ANTIBODY BASED THERAPIES
Pre-clinical 
Being Developed by Sanofi Link here

A STUDY OF CC-98633, BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED AND/OR  REFRACTORY MULTIPLE MYELOMA
NCT04394650; 
Multi-center phase I of BCMA-Targeted CARs using NEX-T manufacturing

A STUDY OF CC-95266 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
NCT04674813; DFCI PI Omar Nadeem
Multi-center phase I of GPRC5D-Targeted CARs

G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D) TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
NCT04555551; Mailankody S PI
Phase I single center study at Memorial Sloan Kettering Cancer Center of MCARH109

STUDY EVALUATING THE SAFETY AND EFFICACY OF JCARH125 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (EVOLVE)
NCT03430011; Mailankody S et al ASH 2018a; Mailankody S et al ASCO 2020
Multi-center phase II study of Orvacabtagene autoleucel (formerly JCARH125)

BCMA TARGETED CAR T CELLS WITH OR WITHOUT LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
NCT03070327; Mailankody S et al ASH 2018b
Phase I single center study at Memorial Sloan Kettering Cancer Center of MCARH171

IMMUNOTHERAPY WITH BCMA CAR-T CELLS IN TREATING PATIENTS WITH BCMA POSITIVE RELAPSED OR REFRACTORY MULTIPLE MYELOMA
NCT03338972; Green D et al ASH 2018; Green D et al ASH 2019
Phase I single center study at Fred Hutchinson Cancer Research Center using FCARH143

BCMA-SPECIFIC CAR T-CELLS COMBINED WITH A GAMMA SECRETASE INHIBITOR (JSMD194) TO TREAT RELAPSED OR PERSISTENT MULTIPLE MYELOMA
​NCT03502577; Cowan A et al ASH 2019
Phase I single center study at Fred Hutchinson Cancer Research Center using FCARH143